JP4375946B2 - Anti-obesity composition comprising peanut astringent skin extract as active ingredient - Google Patents

Description

[0001]
BACKGROUND OF THE INVENTION
The present invention has a lipase inhibitory action, a cyclic AMP phosphodiesterase inhibitory action, an α-glucosidase inhibitory action or an α-amylase inhibitory action and is useful for the prevention and treatment of obesity (for example, a pharmaceutical composition, Food and beverage composition, feed composition, cosmetic composition, etc.).
[0002]
[Prior art]
In recent years, body fat has increased due to lifestyle habits such as satiety and lack of exercise, and obesity has increased. Such an increase in obesity is seen not only in humans but also in pets and livestock. Obesity is a cause of adult diseases such as hyperlipidemia and arteriosclerosis, which is not only a cosmetic problem but also a major problem in health.
[0003]
Examples of obesity prevention / treatment methods include restriction of dietary intake and fat burning by various aerobic exercises. These methods are not effective because they are not only difficult to obtain an effect in a short period of time, but also involve physical and mental distress. Therefore, obesity prevention / treatment methods using anti-obesity compositions (for example, pharmaceutical compositions, food and beverage compositions, feed compositions, cosmetic compositions) are generally used.
[0004]
As an active ingredient of the composition for anti-obesity, an enzyme involved in carbohydrate or fat metabolism, for example, a substance that inhibits the activity of lipase, cyclic AMP phosphodiesterase, α-glucosidase, α-amylase, etc. is used. Examples of such an inhibitory substance include compounds such as caffeine and tetracycline, various plant extracts (for example, JP-A 64-90131, JP-A-1-102202, JP-A-3-219872, and JP-A-5-20772). 255100, JP-A-10-262606) and the like are known.
However, since any anti-obesity composition has problems such as side effects, low safety, and low anti-obesity effect, development of a novel anti-obesity composition is desired. .
[0005]
[Problems to be solved by the invention]
Therefore, the present invention finds a substance having a lipase inhibitory action, a cyclic AMP phosphodiesterase inhibitory action, an α-glucosidase inhibitory action or an α-amylase inhibitory action from among highly safe natural products, and uses it as an active ingredient An object is to provide a novel anti-obesity agent .
[0006]
[Means for Solving the Problems]
In order to solve the above problems, the present invention provides an anti-obesity agent characterized by containing a peanut astringent skin extract as an active ingredient.
[0007]
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, the present invention will be described in detail.
In the present invention, the “peanut astringent skin extract” refers to an extract obtained from peanut astringent skin as an extraction raw material, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, or a rough product thereof. Either a purified product or a purified product is included.
[0008]
Peanut (Arachis hypogaea LINNE) is a plant belonging to the legume family, and the peanut astringent skin is also called thin skin or cuticle. Peanut astringent skin is always discarded when peanuts are processed into various foods, especially when producing peanut butter, a huge amount of astringent skin is produced as waste. Was little known and was disposed of as waste. It has been known that peanut astringent skin contains a component having a glucosyltransferase inhibitory action (Japanese Patent Laid-Open No. 2000-178158), but a lipase inhibitory action, a cyclic AMP phosphodiesterase inhibitory action, an α-glucosidase inhibitory action or It has not been known so far that a component having an α-amylase inhibitory action is contained.
[0009]
Details of substances having lipase inhibitory action, cyclic AMP phosphodiesterase inhibitory action, α-glucosidase inhibitory action or α-amylase inhibitory action contained in peanut astringent skin are not known, but are commonly used for plant extraction By the method, an extract having a lipase inhibitory action, a cyclic AMP phosphodiesterase inhibitory action, an α-glucosidase inhibitory action or an α-amylase inhibitory action can be obtained from the peanut astringent skin. For example, it can be obtained by drying the raw material for extraction and pulverizing it as it is or using a crusher and subjecting it to extraction with an extraction solvent. At this time, the extraction raw material may be dried in the sun or using a commonly used dryer. Peanut astringent skin may be used as a raw material for extraction after pretreatment such as degreasing with a nonpolar solvent such as hexane or benzene. By performing pretreatment such as degreasing, the extraction treatment with the polar solvent of the peanut astringent skin can be performed efficiently.
[0010]
As the extraction solvent, it is preferable to use a polar solvent, and it is particularly preferable to use water, a hydrophilic organic solvent, or a mixture thereof at room temperature or a temperature not higher than the boiling point of the solvent.
[0011]
Examples of water that can be used as the extraction solvent include pure water, tap water, well water, mineral spring water, mineral water, hot spring water, spring water, fresh water, and the like, as well as water that has been subjected to various treatments. Examples of the treatment applied to water include purification, heating, sterilization, filtration, ion exchange, adjustment of osmotic pressure, buffering, and the like. Therefore, the water that can be used as the extraction solvent in the present invention includes purified water, hot water, ion-exchanged water, physiological saline, phosphate buffer, phosphate buffered saline, and the like.
[0012]
Examples of the hydrophilic organic solvent that can be used as the extraction solvent include lower aliphatic alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propyl alcohol, isopropyl alcohol, and butanol; 1,3-butylene glycol, propylene glycol, and glycerin. A lower aliphatic ketone such as acetone or methyl ethyl ketone; or a mixture thereof.
[0013]
When a mixture of two or more kinds of polar solvents is used as the extraction solvent, the mixing ratio can be adjusted as appropriate. For example, when a mixture of water and a lower aliphatic alcohol is used, the mixing ratio of water and the lower aliphatic alcohol can be set to 100: 0 to 10:90 (weight ratio).
[0014]
It is not necessary to adopt a special extraction method to obtain an extract having a lipase inhibitory action, a cyclic AMP phosphodiesterase inhibitory action, an α-glucosidase inhibitory action or an α-amylase inhibitory action from peanut astringent skin, at room temperature or under reflux heating It can be extracted using any device.
[0015]
Specifically, the extraction raw material is put into a treatment tank filled with the extraction solvent, and after standing for 1 to 3 hours with occasional stirring as necessary to elute soluble components, the solid matter is removed by filtration. By doing so, an extract is obtained. At this time, the amount of the extraction solvent is usually 10 to 100 times (weight ratio) of the extraction raw material, and the extraction temperature is usually 30 to 100 ° C.
[0016]
Since the obtained extract is light brown and has a mild taste and smell, it can be used as an active ingredient in an anti-obesity composition as it is, but a concentrated solution or a dried product thereof is more useful. It's easy to do. Moreover, since the active ingredient is not removed even if the extract is treated with activated carbon, the extract may be subjected to deodorization / decolorization treatment with activated carbon. Further purification by adsorption resin treatment, ion exchange resin treatment, or the like can be performed as necessary as long as it is effective for improving the activity of the extract.
[0017]
The peanut astringent peel extract obtained as described above has one or more kinds of actions selected from the group consisting of lipase inhibitory action, cyclic AMP phosphodiesterase inhibitory action, α-glucosidase inhibitory action and α-amylase inhibitory action. By utilizing this action, the peanut astringent skin extract can be used as an active ingredient of the anti-obesity composition. The “active ingredient” means an ingredient that contributes to the anti-obesity effect of the anti-obesity composition, and as long as the peanut astringent skin extract can contribute to the anti-obesity effect of the anti-obesity composition, the peanut astringent skin extract Does not need to be the main component of the anti-obesity composition, and the anti-obesity composition may contain components that contribute to the anti-obesity effect in addition to the peanut astringent skin extract.
[0018]
The form of the composition for anti-obesity may be any form for internal use or external use as long as the anti-obesity effect (obesity prevention / treatment effect) can be exhibited. Specific examples thereof include pharmaceutical compositions, A food / beverage composition, a feed composition, a cosmetic composition and the like can be mentioned.
Components other than the peanut astringent skin extract of the anti-obesity composition can be appropriately selected according to the form of the composition.
[0019]
For example, the pharmaceutical composition may contain pharmaceutically acceptable excipients and other auxiliary agents (for example, bases, extenders, diluents, emulsifiers, dispersants, solvents, etc.) in the peanut astringent skin extract. Can be manufactured. Examples of the dosage form of the pharmaceutical composition include powder, granule, tablet, liquid and the like. The peanut astringent skin extract thus formulated is not only useful as an anti-obesity agent, but also useful as a lipase inhibitor, cyclic AMP phosphodiesterase inhibitor, α-glucosidase inhibitor, and α-amylase inhibitor. . The lipase inhibitor and the cyclic AMP phosphodiesterase inhibitor are useful not only for the prevention / treatment of obesity but also for the prevention / treatment of inflammatory diseases such as dermatitis.
[0020]
The food / beverage composition and the feed composition are prepared from peanut astringent skin extract, for example, sugars such as dextrin and starch; proteins such as gelatin, soybean protein and corn protein; amino acids such as alanine, glutamine and isoleucine; cellulose and gum arabic It can manufacture by mix | blending oils and fats, such as polysaccharides, such as soybean oil and a medium chain fatty acid triglyceride.
[0021]
The food / beverage composition can also be produced by blending the peanut astringent skin extract into any food / beverage product that does not hinder its activity. Foods and drinks that can be blended with the peanut astringent skin extract are not particularly limited, and specific examples thereof include beverages such as soft drinks, carbonated drinks, nutritional drinks, fruit drinks, and lactic acid drinks (concentrated concentrates and adjusting powders of these drinks) Ice cream, ice sherbet, shaved ice and other frozen desserts; buckwheat noodles, udon, harusame, gyoza skin, cucumber skin, Chinese noodles, instant noodles and other noodles; rice cakes, chewing gum, candy, gum, chocolate, tablet confectionery Confectionery such as snacks, biscuits, jelly, jam, cream, baked confectionery; processed fishery and livestock products such as kamaboko, ham, sausage; dairy products such as processed milk, fermented milk; salad oil, tempura oil, margarine, mayonnaise, Shortening, whipped cream, oils and fats such as dressings and processed foods; seasonings such as sauces and sauces; Flop, stew, salad, prepared foods, pickles, bread and the like. Although a peanut astringent skin extract may be mix | blended with the food / beverage products which do not contain saccharide | sugar and a lipid, it is preferable to mix | blend with the food / beverage products containing saccharide | sugar or a lipid. The food / beverage product composition thus produced can be used not only as a food / beverage product for anti-obesity but also as a food / beverage product for the purpose of beauty such as beautiful skin and slimming, that is, a food / beverage product for beauty.
[0022]
The feed composition can also be produced by blending the peanut astringent skin extract with any feed that does not interfere with its activity. Although the feed which can mix | blend a peanut astringent skin extract is not specifically limited, As a specific example, pet food, livestock feed, fish culture feed, etc. are mentioned.
[0023]
Cosmetic compositions include peanut astringent skin extracts such as astringents, bactericides / antibacterial agents, whitening agents, UV absorbers, moisturizers, cell activators, anti-inflammatory / antiallergic agents, antioxidant / active oxygen scavengers, It can be produced by blending oils and fats, waxes, hydrocarbons, fatty acids, alcohols, esters, surfactants, perfumes and the like.
The cosmetic composition can also be produced by blending the peanut astringent skin extract into any cosmetic that does not hinder its activity. Although the cosmetics which can mix | blend a peanut astringent skin extract are not specifically limited, The skin cosmetics, such as an ointment, cream, milky lotion, a lotion, a pack, a bath agent, a lip balm, and a lipstick, are mentioned as the specific example.
[0024]
The peanut astringent skin extract has a slight astringency, but when this astringency is an obstacle to the administration of a pharmaceutical composition, a food or beverage composition or a feed composition, cyclodextrin, dextrin, lactose, sugar alcohol (For example, sorbitol, maltitol, erythritol, xylitol, etc.) can be blended to mask the astringency.
[0025]
When producing an anti-obesity composition, a lipase inhibitor, a cyclic AMP phosphodiesterase inhibitor, an α-glucosidase inhibitor and an α-amylase inhibitor other than peanut astringent skin extract may be used in combination as an active ingredient. Specific examples of active ingredients that can be incorporated into the anti-obesity composition include gymnema sylvestre, garcinia cambodia, capsaicin, chitosan, conjugated linoleic acid (CLA), L-carnitine, ornithine, tea extract, chromium and the like.
[0026]
The blending amount of the peanut astringent skin extract in the anti-obesity composition can be appropriately adjusted according to the form of the composition, the activity of the extract, and the like. For example, when a standard peanut astringent skin extract is blended as it is, a suitable blending ratio is about 0.01 to 20.0 wt%, and a particularly preferable blending ratio is about 0.1 to 5.0 wt%. is there.
[0027]
【Example】
Hereinafter, the present invention will be described in more detail with reference to examples. In each example, “parts” means parts by weight.
[0028]
[Production Example 1]
To 100 g of dried peanut astringent skin, 1000 mL of water was added as an extraction solvent and heated in a boiling water bath for 2 hours to extract soluble components. The obtained extract was concentrated to dryness under reduced pressure to obtain 10 g (powder) of solid extract. (Yield 10%)
[0029]
[Production Example 2]
To 100 g of dried peanut astringent skin, 1200 mL of 60% aqueous ethanol was added as an extraction solvent, and heated at 60 ° C. for 2 hours to extract soluble components. The obtained extract was concentrated to dryness under reduced pressure to obtain 15 g (powder) of solid extract. (Yield 15%) The extraction solvent is preferably water or water-containing alcohol in consideration of workability, economy and safety, and the amount of extraction solvent is preferably 5 to 50 times the extraction solvent. It is thought that 30-100 degreeC is preferable.
[0030]
[Test Example 1] Lipase Inhibitory Activity Test A sample solution was prepared by dissolving the water extract of peanut astringent skin and 60% ethanol extract obtained in Production Examples 1 and 2 in 50 wt% ethanol.
50 μL of each sample solution, 50 μL of lipase (Candida cylindracea origin, Biocatalysts; 15.4 U / mL), 5,5′-dithiobis (2-nitro-benzoic acid) dissolved in 0.1 M Tris-HCl buffer (pH 8.5) ) (DTNB, 0.1 mg / mL) 340 μL and phenylmethylsulfonyl fluoride (PMSF, 3.5 mg / mL) 10 μL dissolved in ethanol were mixed well and allowed to stand at 30 ° C. for 5 minutes. After adding 25 μL each of 2,3-dimercapto-1-propanol tributylate (BALB, 0.3 mg / mL) and sodium dodecylsulfate (SDS, 0.26 mg / mL) dissolved in ethanol to the enzyme reaction solution, 30 The reaction was carried out at 30 ° C. for 30 minutes. After adding 500 μL of acetone to stop the enzyme reaction, the absorbance at a wavelength of 414 nm proportional to the amount of hydrolysis of BALB was measured. As a control, the same operation and absorbance measurement were performed when 50 wt% ethanol was added instead of the sample solution.
From the measurement results, the lipase activity inhibition rate was calculated by the following formula.
[0031]
Inhibition rate (%) = 1-[(A1-A0) / (A3-A2)] × 100
[0032]
In the above formula, “A0” is the absorbance when the sample solution is added (before the start of the enzyme reaction), “A1” is the absorbance when the sample solution is added (after the start of the enzyme reaction), and “A2” is the absorbance of the control (after the start of the enzyme reaction). “A3” represents the absorbance of the control (after the start of the enzyme reaction).
[0033]
The lipase activity inhibition rate is measured by changing the sample concentration of the sample solution stepwise from 100 to 2000 μg / mL, and the sample concentration (IC ₅₀ ) (μg / mL) of the sample solution at which the inhibition rate becomes 50% is determined. Asked. As a result, the IC ₅₀ when using the water extract of peanut astringent skin was 1800 μg / mL, and the IC ₅₀ when using a 60% ethanol extract of peanut astringent skin was 1500 μg / mL.
[0034]
From this result, it was confirmed that the peanut astringent skin extract has a lipase inhibitory action. Moreover, it was confirmed that the strength of the lipase inhibitory action of the peanut astringent skin extract can be adjusted by the concentration of the extract.
[0035]
[Test Example 2] Cyclic AMP phosphodiesterase inhibitory activity test Sample solution prepared by dissolving the water extract of peanut astringent skin and 60% ethanol extract obtained in Production Examples 1 and 2 in Tris-HCl buffer containing no magnesium chloride Was prepared.
To 0.2 mL of Tris-HCl buffer (pH 7.5) containing 5 mM magnesium chloride, 0.1 mL of fetal serum albumin solution and 0.1 mL of cyclic AMP phosphodiesterase solution were added, and 0.05 mL of each sample solution was further added. Preincubation at 5 ° C. for 5 minutes. Subsequently, 0.05 mL of cyclic AMP solution was added and incubated at 37 ° C. for 60 minutes. The reaction was stopped by boiling for 3 minutes in a boiling bath, and centrifuged at 4500C at 3500 rpm, and the reaction substrate and 5'-AMP in the supernatant were quantified by high performance liquid chromatography. As a control, the same enzyme reaction and analysis of the reaction substrate were performed without adding the sample solution. Based on the ratio of the reactive group mass when the sample solution was added to the reactive group mass when the sample solution was not added, The cyclic AMP phosphodiesterase inhibition rate (%) was determined.
[0036]
The conditions for high performance liquid chromatography are as follows.
Detector: UV absorption detector (measurement wavelength 260 nm)
Column packing: 10 μm chemically bonded octadecylsilane column tube: stainless steel tube with inner diameter of 4.6 mm and length of 250 mm Column temperature: 40 ° C.
Mobile phase: acetonitrile / 1 mM TBAP (25 mM KH ₂ PO ₄ ) = 10/90 (weight ratio) Mixed liquid flow rate: 1 mL / min
Inhibition rate (%) = 1-[(A1-A0) / (A3-A2)] × 100
[0038]
In the above formula, “A0” is the amount of the reaction product when the sample solution is added (before the start of the enzyme reaction), “A1” is the amount of the reaction product when the sample solution is added (after the start of the enzyme reaction), and “A2” is The amount of the control reaction product (before the start of the enzyme reaction), “A3” represents the amount of the control reaction product (after the start of the enzyme reaction).
[0039]
The cyclic AMP phosphodiesterase inhibition rate is measured by changing the sample concentration of the sample solution stepwise from 50 to 200 μg / mL, and the sample concentration (IC ₅₀ ) (μg / mL) of the sample solution at which the inhibition rate becomes 50%. ) As a result, the IC ₅₀ when using a water extract of peanut astringent skin was 140.5 μg / mL, and the IC ₅₀ when using a 60% ethanol extract of peanut astringent skin was 103.7 μg / mL.
[0040]
From this result, it was confirmed that the peanut astringent skin extract has a cyclic AMP phosphodiesterase inhibitory action. Moreover, it was confirmed that the strength of the cyclic AMP phosphodiesterase inhibitory action of the peanut astringent skin extract can be adjusted by the concentration of the extract.
[0041]
[Test Example 3] α-Glucosidase Inhibitory Activity Test A sample solution was prepared by dissolving the water extract of peanut astringent skin and 60% ethanol extract obtained in Production Examples 1 and 2 in 50 wt% ethanol.
To 50 μL of each sample solution, 300 μL of 10 mM sucrose or maltose solution dissolved in 0.1 M phosphate buffer (pH 7.0) was added, mixed well, and pre-incubated at 37 ° C. for 5 minutes. Subsequently, α-glucosidase-containing small intestinal fluid (1 g of rat small intestine acetone powder was added to 10 mL of 0.1 M phosphate buffer (pH 7.0), stirred with a stirrer (4 ° C., 1 hour), and centrifuged. (Supernatant separated by 3,500 rpm, 15 minutes) 30 μL was added and reacted at 37 ° C. for 30 minutes. After boiling in boiling water for 3 minutes, the reaction was stopped, centrifuged at 4 ° C., and glucose as a reaction product in the supernatant was quantified with Glucose Test Wako (Wako Pure Chemical Industries, Ltd.). As a control, the same enzyme reaction and analysis of the reaction product were performed without adding the sample solution, and the following formula was calculated from the ratio of the reaction product amount when the sample solution was added to the reaction product amount when the sample solution was not added. Based on this, α-glucosidase inhibition rate (%) was calculated.
[0042]
Inhibition rate (%) = 1-[(A1-A0) / (A3-A2)] × 100
[0043]
In the above formula, “A0” is the amount of glucose when the sample solution is added (before the enzyme reaction is started), “A1” is the amount of glucose when the sample solution is added (after the start of the enzyme reaction), and “A2” is the control The amount of glucose (before the start of the enzyme reaction), “A3” represents the amount of control glucose (after the start of the enzyme reaction).
[0044]
The α-glucosidase inhibition rate is measured by changing the sample concentration of the sample solution stepwise from 50 to 400 μg / mL, and the sample concentration (IC ₅₀ ) of the sample solution at which the inhibition rate becomes 50% (μg / mL) Asked. As a result, the IC ₅₀ when using a water extract of peanut astringent skin was 280 μg / mL when the substrate was sucrose, 310 μg / mL when the substrate was maltose, and a 60% ethanol extract of peanut astringent skin was used. The IC ₅₀ for the case was 220 μg / mL when the substrate was sucrose and 240 μg / mL when the substrate was maltose.
[0045]
From this result, it was confirmed that the peanut astringent skin extract has an α-glucosidase inhibitory action. Moreover, it was confirmed that the strength of the α-glucosidase inhibitory action of the peanut astringent skin extract can be adjusted by the concentration of the extract.
[0046]
[Test Example 4] α-Amylase Inhibitory Activity Test A water solution of peanut astringent skin and 60% ethanol extract obtained in Production Examples 1 and 2 were dissolved in water to prepare a sample solution.
50 μL of each sample solution contains 250 μL of 0.5% soluble starch solution dissolved in 50 mM acetate buffer buffer (pH 5.5), 50 μL of α-amylase solution (derived from human saliva), 20 mM potassium chloride and 100 mM sodium chloride 50 μL of 50 mM acetate buffer buffer (pH 5.5) and 100 μL of 50 mM acetate buffer buffer (pH 5.5) were added and reacted at 37 ° C. for 15 minutes. After completion of the reaction, 5 mL of a 0.0017N hydrochloric acid solution containing 1.7 mM potassium iodide and 0.17 mM iodine was added, and the absorbance at 700 nm was measured. As a control, the same enzyme reaction and analysis of the reaction product were performed without adding the sample solution. From the ratio of the reaction product amount when the sample solution was added to the reaction product amount when the sample solution was not added, the following formula was calculated. Based on this, the α-amylase inhibition rate (%) was calculated.
[0047]
Inhibition rate (%) = 1-[(A1-A0) / (A3-A2)] × 100
[0048]
In the above formula, “A0” is the absorbance when the sample solution is added (before the start of the enzyme reaction), “A1” is the absorbance when the sample solution is added (after the start of the enzyme reaction), and “A2” is the absorbance of the control (after the start of the enzyme reaction). “A3” represents the absorbance of the control (after the start of the enzyme reaction).
[0049]
The α-amylase inhibition rate is measured by changing the sample concentration of the sample solution stepwise from 200 to 2000 μg / mL, and the sample concentration (IC ₅₀ ) of the sample solution at which the inhibition rate becomes 50% (μg / mL) Asked. As a result, the IC ₅₀ when using a water extract of peanut astringent skin was 1300 μg / mL, and the IC ₅₀ when using a 60% ethanol extract of peanut astringent skin was 1050 μg / mL.
[0050]
From this result, it was confirmed that the peanut astringent skin extract has an α-amylase inhibitory action. Moreover, it was confirmed that the strength of the α-amylase inhibitory action of the peanut astringent skin extract can be adjusted by the concentration of the extract.
[0051]
[Formulation Example 1] Bread Bread The following ingredients were mixed, fermented, and baked in the usual manner for bread to produce bread having an anti-obesity effect.
Peanut astringent skin extract of Production Example 2 2 parts Strong powder 250 parts Sugar 15 parts Salt 2 parts Unsalted butter 20 parts Nonfat dry milk 5 parts Dry yeast 3 parts Water 200 parts
[Composition Example 2] A koji having anti-obesity action was produced by mixing, concentrating and molding the following raw materials according to a conventional method of koji production.
Peanut astringent skin extract of Production Example 1 1 part Sucrose 70 parts Minamata 30 parts Citric acid 1 part Fragrance 0.1 parts Water 15 parts
[Composition Example 3] Beverage-containing beverages The following ingredients were mixed, dissolved, and filled by a conventional method for producing fruit juice-containing beverages to produce juice-containing beverages having an anti-obesity effect.
Peanut astringent skin extract of Production Example 1 0.5 parts grapefruit juice 0.3 parts fructose glucose liquid sugar 5 parts flavoring 0.01 parts sodium citrate 0.1 parts vitamin C 0.1 parts purified water 95 parts
[Formulation Example 4] Mixed tea The following ingredients were extracted, filtered, and filled by the conventional method of tea to produce tea having anti-obesity activity.
Peanut astringent skin extract of Production Example 1 1 part Oolong tea 2 parts pearl tea 2 parts yellow tea 2 parts Hub Saw 3 parts purified water 90 parts
[Formulation Example 5] Pet food The following raw materials were mixed, molded, and dried by a conventional method for producing pet food to produce a pet food having an anti-obesity action.
5 g peanut astringent skin extract from Production Example 1
10g soybean meal
Soybean oil 5g
5g fish meal
Calcium carbonate 1g
Vitamin B complex 0.1g
Vitamin ADE premix 0.1g
[0056]
【The invention's effect】
According to the present invention, an anti-obesity composition containing a peanut astringent skin extract as an active ingredient is provided. The peanut astringent skin extract inhibits lipase, cyclic AMP phosphodiesterase, α-glucosidase or α-amylase activity involved in carbohydrate or fat metabolism, and suppresses the decomposition and absorption of carbohydrates and lipids taken in the diet. In addition, since peanut is a food material that can be eaten without peeling off the astringent skin, there is no problem with the safety of the astringent skin extract, and there is no fear of exhibiting an undesirable effect on useful intestinal bacteria. Therefore, the anti-obesity composition of the present invention containing peanut astringent skin extract as an active ingredient is useful for the prevention and treatment of obesity.

Claims (2)

An anti-obesity agent comprising peanut astringent skin extract as an active ingredient. 2. The extract according to claim 1, wherein the extract has at least one action selected from the group consisting of a lipase inhibitory action, a cyclic AMP phosphodiesterase inhibitory action, an α-glucosidase inhibitory action, and an α-amylase inhibitory action. Anti-obesity agents .